Novo Nordisk announced that the FDA has approved Victoza (liraglutide [rDNA] injection), a glucagon-like peptide-1 (GLP-1) analog, as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. This approval was based on data from the Phase 3 LEAD (the Liraglutide Effect and Action in Diabetes) trials, which demonstrated significant reductions in A1C in patients treated with Victoza monotherapy and in combination with standard diabetes treatments. Additionally, Victoza therapy was associated with weight loss.
Victoza is expected to be available in 4–6 weeks.
For more information call (800) 727-6500 or visit www.novonordisk.com.